Prestige BioPharma Limited
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in im… Read more
Prestige BioPharma Limited (950210) - Total Liabilities
Latest total liabilities as of September 2025: ₩215.44 Billion KRW
Based on the latest financial reports, Prestige BioPharma Limited (950210) has total liabilities worth ₩215.44 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Prestige BioPharma Limited - Total Liabilities Trend (2018–2025)
This chart illustrates how Prestige BioPharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Prestige BioPharma Limited Competitors by Total Liabilities
The table below lists competitors of Prestige BioPharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HMA AGRO INDUSTRIES ORD (BSE)
NSE:HMAAGRO
|
India | ₹8.82 Billion |
|
Spyrosoft S.A.
WAR:SPR
|
Poland | zł89.73 Million |
|
West Vault Mining Inc
OTCQX:WVMDF
|
USA | $14.01 Million |
|
I&C Technology Co. Ltd
KQ:052860
|
Korea | ₩16.71 Billion |
|
VRX Silica Ltd
AU:VRX
|
Australia | AU$698.85K |
|
Ausquest Ltd
AU:AQD
|
Australia | AU$2.05 Million |
|
Red Pine Exploration Inc
OTCQB:RDEXF
|
USA | $1.55 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Prestige BioPharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prestige BioPharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prestige BioPharma Limited (2018–2025)
The table below shows the annual total liabilities of Prestige BioPharma Limited from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | ₩236.15 Billion | +20.35% |
| 2024-06-30 | ₩196.22 Billion | +0.44% |
| 2023-06-30 | ₩195.37 Billion | +179.58% |
| 2022-06-30 | ₩69.88 Billion | +139.26% |
| 2021-06-30 | ₩29.21 Billion | +30.98% |
| 2020-06-30 | ₩22.30 Billion | -50.16% |
| 2019-06-30 | ₩44.74 Billion | +237.37% |
| 2018-06-30 | ₩13.26 Billion | -- |